Cue Biopharma, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Cue is a clinical-stage biopharmaceutical company developing Immuno-STAT biologics; it has no commercial product revenue and continues to incur operating losses.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / prior period |
|---|---|---|
| Collaboration revenue | $0.187 million | $1.000 million |
| Operating expenses | $13.567 million | $15.238 million |
| Operating loss | $13.380 million | $14.238 million |
| Net loss | $13.109 million | $14.255 million |
| Net loss per share, basic and diluted | $0.29 | $0.44 |
| Cash used in operating activities | $10.833 million | $11.573 million |
At March 31, 2023, cash and cash equivalents were $56.321 million and marketable securities were $9.878 million, totaling $66.199 million. Current assets were $68.755 million and current liabilities $13.810 million. Total assets were $81.682 million; stockholders’ equity was $55.017 million.
Debt had a carrying value of approximately $10.040 million, including current and long-term portions. The $10 million term loan bore 10.25% interest at quarter-end; principal repayment was scheduled to begin June 30, 2023. The loan is secured by substantially all company assets, subject to an intellectual-property negative pledge, and includes a cash-maintenance covenant. The loan was amended in April 2023; the filing text provided here does not clearly state the amendment’s terms.
Material changes and business developments
- Revenue declined $0.813 million year over year, primarily because the LG Chem research phase ended on March 31, 2022. Q1 2023 revenue included approximately $36,000 from LG Chem and $151,000 from Ono.
- Operating expenses decreased $1.671 million. General and administrative expense fell $0.980 million, and research and development expense fell $0.691 million, chiefly due to lower stock-based compensation and selected facility, manufacturing, and professional costs.
- Interest income rose to $0.641 million from $0.008 million, while interest expense increased to $0.370 million from $0.025 million, mainly reflecting the term loan.
- Cash and marketable securities totaled $66.199 million, down from $76.289 million at December 31, 2022. Cash increased during the quarter partly because $15 million of short-term investments were redeemed; this was an investing cash flow, not operating cash generation.
- Common shares outstanding were 43.178 million at March 31, 2023. The company also had 9.188 million common warrants and 1.531 million pre-funded warrants outstanding.
Outlook, programs, and risks
- Management said available cash, cash equivalents, and marketable securities were expected to fund operations for at least 12 months from issuance of the financial statements. The company expects to need additional capital thereafter; actual runway may be shorter if assumptions do not hold.
- Ono’s February 2023 agreement funds CUE-401 research through an option period of up to 24 months. Ono paid a $3 million upfront amount and agreed to reimburse research costs under specified terms. If Ono exercises its option, Cue may receive additional option, milestone, and royalty payments; the agreement includes potential milestones of up to approximately $220 million. These amounts are contingent, not assured revenue.
- Cue prioritized CUE-101 and CUE-102 in its oncology pipeline and is seeking partners or other support for CUE-103, Neo-STAT, RDI-STAT, and other programs. It reported that CUE-102’s Phase 1 dose-escalation trial was expected to complete that portion in mid-2023.
- Company-reported preliminary CUE-101 results included one confirmed partial response and seven patients with durable stable disease among 19 evaluable monotherapy patients at the recommended Phase 2 dose. In the first 10 evaluable patients in the combination study with pembrolizumab, Cue reported four confirmed partial responses. These are early clinical observations, not evidence of approval or established efficacy; the company anticipated a further update at ASCO in June 2023.
- Key risks include clinical and regulatory uncertainty, dependence on external manufacturers and trial providers, competition, reliance on future financing and collaborations, potential dilution, and loan covenants. The company reported no material legal proceedings, no contingent-liability accruals, and effective disclosure controls as of March 31, 2023.
Important facts for investors to verify
- Whether subsequent clinical updates support the preliminary CUE-101 findings and the expected CUE-102 development timeline.
- Actual cash burn and financing needs relative to management’s at-least-12-month runway estimate.
- The April 2023 loan amendment’s final terms, repayment schedule, and covenant implications.
- Ono’s research funding, CUE-401 progress, and any decision to exercise its option; potential milestones and royalties remain conditional.
- Potential dilution from outstanding warrants, pre-funded warrants, stock options, and any future equity financing.